
MarÃ-a José EscÃ;mez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4997449/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	In vitro and In vivo Wound Healing-Promoting Activities of Human Cathelicidin LL-37. Journal of Investigative Dermatology, 2008, 128, 223-236.	0.3	284
2	Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation, 2004, 77, 350-355.	0.5	168
3	Expression of Type 2 Iodothyronine Deiodinase in Hypothyroid Rat Brain Indicates an Important Role of Thyroid Hormone in the Development of Specific Primary Sensory Systems. Journal of Neuroscience, 1999, 19, 3430-3439.	1.7	160
4	An In Vivo Model of Wound Healing in Genetically Modified Skin-Humanized Mice. Journal of Investigative Dermatology, 2004, 123, 1182-1191.	0.3	104
5	Inhibition of Xenografted Human Melanoma Growth and Prevention of Metastasis Development by Dual Antiangiogenic/Antitumor Activities of Pigment Epithelium-Derived Factor. Cancer Research, 2004, 64, 5632-5642.	0.4	93
6	Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. British Journal of Dermatology, 2020, 182, 574-592.	1.4	88
7	Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing. Molecular Therapy, 2019, 27, 986-998.	3.7	76
8	Transcriptional induction of RC3/neurogranin by thyroid hormone: differential neuronal sensitivity is not correlated with thyroid hormone receptor distribution in the brain. Molecular Brain Research, 1997, 49, 37-44.	2.5	71
9	A cutaneous gene therapy approach to treat infection through keratinocyteâ€ŧargeted overexpression of antimicrobial peptides. FASEB Journal, 2004, 18, 1931-1933.	0.2	62
10	The first <i>COL7A1</i> mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation. British Journal of Dermatology, 2010, 163, 155-161.	1.4	53
11	Revertant Mosaicism Due to a Second-Site Mutation in COL7A1 in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2010, 130, 2407-2411.	0.3	51
12	Assessment of Optimal Virus-Mediated Growth Factor Gene Delivery for Human Cutaneous Wound Healing Enhancement. Journal of Investigative Dermatology, 2008, 128, 1565-1575.	0.3	46
13	Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancerâ€prone genodermatoses. British Journal of Dermatology, 2019, 181, 512-522.	1.4	46
14	Induction of Scleroderma Fibrosis in Skinâ€Humanized Mice by Administration of Antiâ^'Plateletâ€Đerived Growth Factor Receptor Agonistic Autoantibodies. Arthritis and Rheumatology, 2016, 68, 2263-2273.	2.9	42
15	Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2014, 134, 2097-2104.	0.3	40
16	Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget, 2014, 5, 1439-1451.	0.8	35
17	Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells. Molecular Therapy - Nucleic Acids, 2018, 11, 68-78.	2.3	35
18	Modeling normal and pathological processes through skin tissue engineering. Molecular Carcinogenesis, 2007, 46, 741-745.	1.3	34

MarÃa José EscÃimez

#	Article	IF	CITATIONS
19	The regenerative potential of fibroblasts in a new diabetesâ€induced delayed humanised wound healing model. Experimental Dermatology, 2013, 22, 195-201.	1.4	34
20	Two novel recessive mutations in KRT14 identified in a cohort of 21 Spanish families with epidermolysis bullosa simplex. British Journal of Dermatology, 2011, 165, 683-692.	1.4	24
21	Prevalence of Dystrophic Epidermolysis Bullosa in Spain: A Population-Based Study Using the 3-Source Capture–Recapture Method. Evidence of a Need for Improvement in Care. Actas Dermo-sifiliogrÃjficas, 2013, 104, 890-896.	0.2	23
22	Long-Term Survival of Type XVII Collagen Revertant Cells in an Animal Model of Revertant Cell Therapy. Journal of Investigative Dermatology, 2014, 134, 571-574.	0.3	23
23	A Comparison of Targeting Performance of Oncoretroviral Versus Lentiviral Vectors on Human Keratinocytes. Human Gene Therapy, 2003, 14, 1579-1585.	1.4	21
24	Keratinocyte cell lines derived from severe generalized recessive <scp>E</scp> pidermolysis <scp>B</scp> ullosa patients carrying a highly recurrent <i><scp>COL</scp>7A1</i> homozygous mutation: models to assess cell and gene therapies <i>in vitro</i> and <i>in vivo</i> . Experimental Dermatology, 2013, 22, 601-603.	1.4	20
25	A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa families. BMC Medical Genetics, 2010, 11, 139.	2.1	18
26	Epidermolysis Bullosa Simplex with Mottled Pigmentation: A Family Report and Review. Pediatric Dermatology, 2013, 30, e125-31.	0.5	17
27	Assessment of the risk and characterization of non-melanoma skin cancer in Kindler syndrome: study of a series of 91 patients. Orphanet Journal of Rare Diseases, 2019, 14, 183.	1.2	16
28	Diagnóstico genético de la epidermólisis bullosa: recomendaciones de un grupo español de expertos. Actas Dermo-sifiliográficas, 2018, 109, 104-122.	0.2	14
29	Skin gene therapy for acquired and inherited disorders. Histology and Histopathology, 2006, 21, 1233-47.	0.5	14
30	Identification of two rare and novel large deletions in <i><scp>ITGB</scp>4</i> gene causing epidermolysis bullosa with pyloric atresia. Experimental Dermatology, 2016, 25, 269-274.	1.4	11
31	Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20Âyears' experience of a reference centre in Spain. Clinical and Translational Oncology, 2019, 21, 1573-1577.	1.2	11
32	X-Linked Ichthyosis along with Recessive Dystrophic Epidermolysis Bullosa in the Same Patient. Dermatology, 2010, 221, 113-116.	0.9	9
33	Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report. Frontiers in Medicine, 2020, 7, 576558.	1.2	7
34	Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-Î ² antagonist and inhibitor of fibrosis. Matrix Biology, 2022, 111, 189-206.	1.5	7
35	A Recurrent Nonsense Mutation Occurring as a de novo Event in a Patient with Recessive Dystrophic Epidermolysis Bullosa. Dermatology, 2011, 223, 219-221.	0.9	6
36	Recessive dystrophic epidermolysis bullosa: the origin of the c.6527insC mutation in the Spanish population. British Journal of Dermatology, 2013, 168, 226-229.	1.4	6

MarÃa José EscÃimez

#	Article	IF	CITATIONS
37	Transcriptomic Analysis of a Diabetic Skin-Humanized Mouse Model Dissects Molecular Pathways Underlying the Delayed Wound Healing Response. Genes, 2021, 12, 47.	1.0	6
38	Genomic expression differences between cutaneous cells from red hair color individuals and black hair color individuals based on bioinformatic analysis. Oncotarget, 2017, 8, 11589-11599.	0.8	5
39	Longâ€term skin regeneration in xenografts from <scp>iPSC</scp> teratomaâ€derived human keratinocytes. Experimental Dermatology, 2016, 25, 736-738.	1.4	4
40	Genetic Diagnosis of Epidermolysis Bullosa: Recommendations From an Expert Spanish Research Group. Actas Dermo-sifiliográficas, 2018, 109, 104-122.	0.2	4
41	Natural Occurrence of Autoantibodies against Basement Membrane Proteins in Epidermolysis Bullosa. Journal of Investigative Dermatology, 2022, 142, 2014-2019.e3.	0.3	4
42	Identical <i><scp>COL</scp>71A1</i> heterozygous mutations resulting in different dystrophic epidermolysis bullosa phenotypes. Pediatric Dermatology, 2018, 35, e94-e98.	0.5	3
43	Combined adipose mesenchymal stromal cell advanced therapy resolved a recalcitrant leg ulcer in an 85-year-old patient. Regenerative Medicine, 2020, 15, 2053-2065.	0.8	2
44	DNA Repair and Immune Response Pathways Are Deregulated in Melanocyte-Keratinocyte Co-cultures Derived From the Healthy Skin of Familial Melanoma Patients. Frontiers in Medicine, 2021, 8, 692341.	1.2	2
45	LB1544 Highly efficient, permanent ex vivo correction of RDEB via non-viral CRISPR/Cas9 excision of COL7A1 Exon 80 bearing a prevalent mutation. Journal of Investigative Dermatology, 2018, 138, B13.	0.3	1
46	147†Involvement of the Human Antimicrobial Peptide LL-37 in Wound Repair. Wound Repair and Regeneration, 2008, 13, A28-A48.	1.5	0
47	148—In Vivo Adenoviral Gene Transfer of SPARC in a Skin-Humanized Mouse Wound Healing Model. Wound Repair and Regeneration, 2008, 13, A28-A48.	1.5	0
48	Prevalence of Dystrophic Epidermolysis Bullosa in Spain: A Population-Based Study Using the 3-Source Capture–Recapture Method. Evidence of a Need for Improvement in Care. Actas Dermo-sifiliográficas, 2013, 104, 890-896.	0.2	0
49	116 Comparative transcriptomic analysis of fibroblasts from two sisters with discordant severe generalized recessive dystrophic epidermolysis bullosa phenotype reveals new molecular markers associated with disease severity. Journal of Investigative Dermatology, 2017, 137, S212.	0.3	0
50	169 Olfactory receptors in skin. Localization, specific expression pattern and their potential role in wound healing. Journal of Investigative Dermatology, 2017, 137, S221.	0.3	0
51	581 A close look into the stroma of Squamous Cell Carcinomas from patients with Recessive Dystrophic Epidermolysis Bullosa. Journal of Investigative Dermatology, 2017, 137, S291.	0.3	0
52	582 A study of non-melanoma skin cancer in a series of well-characterized patients with Kindler Syndrome (KS). Journal of Investigative Dermatology, 2017, 137, S292.	0.3	0
53	Fibroblast activation and ECM remodelling in genodermatoses. British Journal of Dermatology, 2019, 181, e66.	1.4	0
54	é⊷伿€§çš®è,╤–…ä,çš"çº╤»´æ⁻细胞活化和 ECM é‡å¡'. British Journal of Dermatology, 2019, 181, e78.	1.4	0

4

#	Article	IF	CITATIONS
55	New guidelines for the diagnosis of epidermolysis bullosa. British Journal of Dermatology, 2020, 182, e98.	1.4	0